Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? (Q34155429)

31 July 2017

1 reference

title

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? (English)

1 reference

31 July 2017

1 reference

1 reference

S Culine

1

1 reference

PubMed ID

11205458

31 July 2017

J P Droz

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

12

1 reference

31 July 2017

1523-1530

1 reference

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

31 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

How is androgen-dependent metastatic prostate cancer best treated?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Treatment options in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Carboplatin in advanced hormone refractory prostatic cancer patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II study of topotecan in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

A phase II trial of irinotecan in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Pyrazoloacridine for the treatment of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Combination chemotherapy in advanced prostate cancer: a silk purse?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Gene therapy--the future is here: a guide to the practicing urologist

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008394823889

7 January 2021

Identifiers

DOI

10.1023/A:1008394823889

1 reference

31 July 2017

1 reference

PubMed ID

11205458